Pre-treatment with P2Y12 inhibition in NSTE-ACS remains controversial because much of the evidence supporting its practice is derived from trials which included patients with stable angina, STE-ACS, and those having received fibrinolysis for STE-ACS [7,8,9,10,11]. The gene discussed is P2RY12; the disease is angina pectoris.